KaloBios Pharmaceuticals

After years of case-building, federal prosecutors will finally meet Martin Shkreli in court Monday, June 26, for a six-week trial. The former hedge-fund manager and pharmaceutical executive will face eight charges of securities and wire fraud, for which he has pleaded not guilty. “I’m...

Shares of KaloBios Pharmaceuticals Inc (NASDAQ: KBIO) have been halted since the company's controversial CEO Martin Shkreli was arrested on fraud charges on December 17. KaloBios has since fired Shkreli and on Monday appealed a decision by the Nasdaq exchange to delist its shares. In the...